The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology

蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖

• 批准号: 10434380
• 负责人: Nina Bhardwaj
• 金额: $ 5.4万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10434380
• 关键词: Address; Basic Science; Cancer Intervention; Clinical; Clinical Investigator; Clinical Oncology; Clinical Research; Clinical Sciences; Clinical Trials; Data Science; Development; Doctor of Philosophy; Entrepreneurship; Environment; Evaluation; Faculty; Funding; Future; Goals; Immunotherapeutic agent; Individual; Institutes; Interdisciplinary Communication; Intervention Trial; Justice; K-Series Research Career Programs; Knowledge; Leadership; Learning; Malignant Neoplasms; Master of Science; Medicine; Mentors; Methodology; Oncologist; Oncology; Outcome; Pharmaceutical Preparations; Population; Professional Competence; Program Development; Research; Research Activity; Research Personnel; SECTM1 gene; Schools; Science; Structure; Talents; Therapeutic; Training; Training and Education; Translational Research; United States National Institutes of Health; anti-racism; anticancer research; cancer immunotherapeutics; cancer therapy; career; career development; drug discovery; education research; equity diversity and inclusion; faculty community; innovation; medical specialties; multidisciplinary; multiple omics; next generation; novel; patient oriented; patient oriented research; pedagogy; precision medicine clinical trials; programs; recruit; resilience; response; social; success; tool

SUMMARY/ABSTRACT: The purpose of our proposed Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology (K12) is to catalyze the clinical and translational research career development of inspired clinical oncologists from diverse oncology specialties and backgrounds, to become future innovative, scientifically grounded and impactful leaders in clinical cancer research and interventional trials. The intent of our K12 is to advance the careers of the next generation of independently funded interdisciplinary Scholars, armed with the methodologic and analytical acumen, scientific knowledge, teaming capacity and career skills required to successfully address specific unmet needs in cancer treatment, which significantly impact our catchment relevant population. Our strongly mentored career development 3 year program for early stage (junior faculty) investigators, will capitalize upon the Tisch Cancer Institute's expertise in cancer immunotherapeutics, novel correlates of immunotherapeutic response, integrative multi- omic platforms to inform drug repositioning approaches; outstanding cadre of Clinical and Translational Mentors; diverse pool of compelling Scholars, and an academically rigorous training environment that prepares the most compelling MD, or MD/PhD junior faculty in clinical oncology for careers in patient oriented research. Our curricular and mentored research activities will additionally leverage institutional strengths in Data Science, Drug Discovery and Precision Medicine: clinical trial methodology; innovative clinical and translational research education and pedagogy, including opportunities to earn a Master's of Science or PhD in Clinical Research, offered through the Clinical Research Education Program in the Graduate School of Biomedical Sciences and CTSA Center for Patient Oriented Research Training, Education and Development (CePORTED); and align with the NIH UNITE and our institutional anti-racist agenda and commitment to recruit and retain talented underrepresented individuals in medicine and science (URiMS). To accomplish our goals, we will pursue the following specific aims: Aim 1: Champion a structured, educational, scholar specific development program to prepare clinical oncologists to conduct cutting edge, hypothesis -driven and practice changing research in cancer therapeutics; Aim 2: Provide Co-Mentored (Basic and Clinical science faculty) and community informed clinical trial research opportunities in therapeutic innovation; Aim 3: Build a patient oriented cancer research learning culture to advance therapeutic innovation by delivering cutting edge multidisciplinary career development opportunities to advance team science, leadership, cross-disciplinary communication, resilience, and entrepreneurship; Aim 4: Advance justice, equity, diversity and inclusion as core tenets of socially responsible clinical investigators; and Aim 5: Implement a comprehensive, rigorous and quality improvement approach, to program, trainee and mentor evaluation, utilizing novel tools, to track milestones as well as outcome metrics of success.

摘要/摘要：我们建议的Tisch癌症研究所(TCI)Paul Calabresi K12的目的 临床肿瘤学职业发展奖(K12)是为了促进临床和转化性研究 来自不同肿瘤学专业和背景的鼓舞人心的临床肿瘤学家的职业发展，以 成为未来临床癌症研究和研究领域的创新、科学和有影响力的领导者 干预性试验。我们K12的目的是推动下一代独立的职业生涯 资助的跨学科学者，拥有方法论和分析敏锐性，科学知识， 成功解决癌症治疗中未得到满足的具体需求所需的团队能力和职业技能， 这对我们的集水区相关人口产生了重大影响。我们强有力的职业发展指导3 针对早期(初级教师)研究人员的一年制计划，将利用Tisch癌症研究所的 在癌症免疫治疗方面的专业知识，免疫治疗反应的新相关性，综合多学科 为药物重新定位方法提供信息的OMIC平台；优秀的临床和翻译干部 导师；多样化的令人信服的学者队伍，以及学术上严格的培训环境 临床肿瘤学方面最有吸引力的医学博士或医学/博士初级教师，从事以患者为中心的研究。 我们的课程和指导研究活动将进一步利用数据科学方面的机构优势， 药物发现和精确医学：临床试验方法学；创新的临床和翻译研究 教育和教育学，包括获得理学硕士或临床研究博士学位的机会； 通过生物医学研究生院的临床研究教育计划提供 CTSA以患者为导向的研究培训、教育和发展中心(CePORTED)；以及ALIGN 随着NIH的团结和我们的机构反种族主义议程以及招聘和留住人才的承诺 在医学和科学界代表性不足的个人(URiMS)。为了实现我们的目标，我们将追求 以下具体目标：目标1：倡导一项有组织的、有教育意义的、学者特有的发展方案，以 培养临床肿瘤学家在以下领域进行前沿、假设驱动和实践变化的研究 癌症治疗学；目标2：提供共同指导(基础和临床科学教员)和社区信息 临床试验研究在治疗创新中的机遇；目标3：建立以患者为中心的癌症研究 学习文化通过提供前沿的多学科职业来推动治疗创新 发展机会促进团队科学、领导力、跨学科沟通、韧性、 和企业家精神；目标4：促进正义、公平、多样性和包容性，作为社会变革的核心原则 负责任的临床研究人员；和目标5：实施全面、严格和质量改进 方法，利用新工具进行规划、受训人员和导师评估，以跟踪里程碑以及 成功的结果衡量标准。